Viva Biotech Holdings (FRA:VB0) Institutional Ownership: 1.69% (As of Jul. 11, 2026)


FRA:VB0 Viva Biotech Holdings FRA:VB0
42 GF Score
Price €0.13
GF Value €0.08
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Viva Biotech Holdings Institutional Ownership?

Viva Biotech Holdings FRA:VB0 +0.76% 42 Institutional Ownership is 1.69% as of Jul. 11, 2026. GuruFocus rates FRA:VB0 with a GF Score™ of 42/100 and a GF Value™ of €0.08 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Viva Biotech Holdings's institutional ownership is 1.69%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Viva Biotech Holdings's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Viva Biotech Holdings's Float Percentage Of Total Shares Outstanding is 0.00%.

Viva Biotech Holdings Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Viva Biotech Holdings's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viva Biotech Holdings Institutional Ownership Chart

Viva Biotech Holdings Historical Data

The historical data trend for Viva Biotech Holdings can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 1.13 1.15 1.18 1.73 1.81 1.81 1.82 1.80 1.68 1.69
FRA:VB0
42GF Score
Viva Biotech Holdings FRA:VB0
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viva Biotech Holdings Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 1.69% mean?
Viva Biotech Holdings (FRA:VB0) has a Institutional Ownership of 1.69% as of Jul. 11, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Viva Biotech Holdings and its competitors.
Is Viva Biotech Holdings' Institutional Ownership too high?
Viva Biotech Holdings' current Institutional Ownership is 1.69%. Overall, Viva Biotech Holdings has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' Institutional Ownership compare to VRTX and REGN?
Viva Biotech Holdings' Institutional Ownership of 1.69% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Viva Biotech Holdings and its competitors. Viva Biotech Holdings's current Institutional Ownership is 1.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.13 — trading 66.3% above its estimated fair value. The current Institutional Ownership is 1.69%. Viva Biotech Holdings' overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current Institutional Ownership is 1.69% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?

Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued. The current stock price of €0.13 is trading 66.3% above its estimated GF Value™ of €0.08. GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.

Key valuation signals for FRA:VB0:

  • Institutional Ownership: 1.69%
  • GF Value™: €0.08 vs. price of €0.13 (66.3% above fair value)
  • GF Score™: 42/100 with 5 warning signs

No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Viva Biotech Holdings Business Description

Other Exchanges VBIZF:USA01873:Hong Kong
Address 735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
42GF Score

Get the complete analysis for FRA:VB0

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.13
Price
€0.08
GF Value